Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective
Duloxetine is a valuable option for patients with OA; however, uncertainties exist in the model, and these suggestions can be adopted with caution.
Authors
- Xueshan Sun (ORCID: https://orcid.org/0000-0002-1115-6815)
- Shuyan Gu (ORCID: https://orcid.org/0000-0002-2362-1251)
- Hengjin Dong (ORCID: https://orcid.org/0000-0002-5064-7297)
- Xuemei Zhen (ORCID: https://orcid.org/0000-0002-1071-7326)
- K Liu (ORCID: https://orcid.org/0000-0001-9346-5162)
- Wenqianzi Yang
Institutions
- Shandong University (CN)
- Wenzhou Medical University (CN)
- The Fourth People's Hospital (CN)
- Shandong Management University (CN)
- Fourth Affiliated Hospital of China Medical University (CN)
- Zhejiang Taizhou Hospital (CN)
- Zhejiang University (CN)
- Xi'an Jiaotong University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1080/14737167.2024.2410973
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00